08/10/2025
Great news.
We are thrilled to share that one of our funded trials has today shared positive results.
HER-096, a potential new Parkinson's treatment, has shown promising phase 1 trial results, proving it’s safe, well-tolerated, and effective in reaching the brain. This is a crucial step towards a drug that could slow, stop, or even repair Parkinson's damage. Dr. Antti Vuolanto, CEO of Herantis Pharma, added:
"These results are a testament to our team’s expertise and dedication, demonstrating our ability to drive the development program forward efficiently.
"We are now excited to advance this program to Phase 2 as we explore HER-096’s potential to become the first disease-modifying therapy for Parkinson’s."
Click to read the full story: https://prksn.uk/4q69nP8